MedTrace Logo

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

NCT01020123 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2012-11-26

Study results available
· View outcomes & findings →

Summary

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients

Conditions

  • Type II Diabetes Mellitus

Interventions

DRUG

AZD1656

Different doses of AZD1656 administered to 5 groups of patients

DRUG

Placebo

AZD1656 placebo and glipizide placebo administered to 1 group of patients

DRUG

Glipizide

Glipizide administered to 1 group of patients

Sponsors & Collaborators

Principal Investigators

  • Eva Johnsson · AstraZeneca R&D Mölndal

  • John Wilding, DM FRCP · University Hospital Aintree

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Chile
  • Germany
  • Hungary
  • Latvia
  • Lithuania
  • Mexico
  • Peru
  • Poland
  • Romania
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01020123 on ClinicalTrials.gov